|
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Asprosin was first reported in 2016 as a fasting-induced protein hormone that modulates hepatic glucose. It is released as the C-terminal cleavage product of profibrillin (P35555). It is secreted by white adipose, circulates at nanomolar levels, and is recruited to the liver, where it activates the G protein-cAMP-PKA pathway, resulting in rapid glucose release into the circulation. The molecular mechanism is unknown but it is suggested asprosin uses a cell-surface receptor system distinct from those used by glucagon and catecholamines [3]. A study published in 2017 suggests that in addition to performing a glucogenic function, asprosin is a centrally acting orexigenic hormone that is a potential therapeutic target in the treatment of both obesity and diabetes [2]. The authors have also filed a patent claiming the potential use of asprosin (or an antobody or inhibitor of asprosin) for the maintenance of optimal body weight and blood glucose [1].
Species: Human
|
Classification  |
|
| Compound class | Endogenous peptide in human, mouse or rat |
| Gene/Precursor |
||||||||||
|
| Database Links |
|
| CATH/Gene3D | 3.90.290.10 |
| Ensembl Gene | ENSG00000166147 (Hs) |
| Entrez Gene | 2200 (Hs) |
| GtoPdb PubChem SID | 315661276 |
| Human Protein Atlas | ENSG00000166147 (Hs) |
| UniProtKB | P35555 (Hs) |
